A 7-year-old child with a diagnosis of LGS has been well-controlled on valproate for the past year. The patient is now being started on CBD as an adjunct therapy to further reduce seizure frequency. Prior to initiating CBD, the patient’s liver function tests showed a slight elevation in transaminases (AST and ALT) and total bilirubin, which has been stable but concerning for potential hepatotoxicity. Given the introduction of CBD and the current liver enzyme elevations, what is the appropriate timeline for monitoring liver function tests (LFTs)? A. Additional monitoring only on clinical status and/or observed changes in enzyme levels B. Monitoring at 1-month post-CBD initiation then at 1- to 2-month intervals depending on clinical status and/or observed changes in enzyme levels C. Monitoring only at 1-month post-CBD initiation, 6-month, and 12-month intervals D. Monitoring only at 1-month post-CBD initiation and 6-month intervals E. Unsure
[Expert Solution]: A 7-year-old child with a diagnosis of LGS…
Need help with your Newborn Care & Neonatology case study or NCLEX preparation? Connect with a verified Nursing expert now.